Article
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Dermatology Times November 2024 Print Recap
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Advances in HS treatment with Chris Sayed, MD
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
New Hydroquinone Pigmentation Alternatives
Polynucleotide Therapy Shows Promise in Scar and Burn Management